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The health challenge of 
the carbapenemase-producing Enterobacteriaceae
Bacterial multiresistance to antibiotics has become a major source of concern for public health in the last years.
The severity of this threat has increased by the fact that research for new antibiotic agents is currently stalled. Carbapenems are
members of the β-lactam family, the latest developed molecules that posses the broadest spectrum of antimicrobial activity and they are
crucial for treating life-threatening infections.
Carbapenemase-producing Enterobacteriaceae (CPE) are progressively spreading throughout the world. The production of carbapenem-
hydrolysing β-lactamases confers resistance to almost all β-lactams and, in most cases; they also carry other non-β-lactam resistance
mechanisms leading to multidrug resistant isolates. Unfortunately, the prevalence of CPE has increased during the past 10 years,
seriously compromising the therapeutic armamentarium and poses a challenge in the treatment and control of these infections.
The aim of this review is to analyze the CPE problematic, to discuss their distinctive traits and to evaluate the current available detection
methods, treatment options and finally, decide which one is the best way forward to address this alarming situation.
Table 1. Main characteristics of carbapenemase-producing Enterobacteriaceae detection methods
Phenotypic methods Molecular methods
Test parameters MHT UV spectrophotometry
MALDI-TOF 
MS Carba NP test
PCR 
techniques
DNA 
Microarray
Efficiency (%)
Sensitivity 100 100 100 100-80 100 98.8
Specificity 87 100 100 100 100 100
Other characteristics
Rapidity (h) 16-24 12-24 2-4 < 2 24-48 8-24
Cost1 $ $ $ $ $$ $$$
Expertise needs2 ++ +++ +++ + ++ ++
Carbapenemase 
detected 
KPC, OXA-
48 and 
NDM (+Zn)
All types (No 
discrimination)
All types All types 
(FNR3for OXA-
48,IMP and 
NDM)
All types (No 
novel)
KPC,VIM, 
NDM,IMP, IMI 
and OXA
1 The number of $’s correlates with the effective (relative) price of the test
2 The number of +’s correlates with the expertise and training needed to perform and interpret the test
3 FNR, false negative results
Carbapenemases
Detection
Treatment
-Class B or metallo- β-lactamases (IMP, VIM, SPM and NDM types) exhibit a broad spectrum of
hydrolytic activity, including all penicilins, cephalosporins and carbapenems. Plasmid encoding
NDM genes can harbor a really high number of associated resistances, they are frequently
acquired by K.pneumoniae and Escherichia coli (Figure 2), two of the most common pathogens,
and they arise from high density and low-income zones like the sub-Indian continent or Pakistan.
These traits have made NDM enzymes of extraordinary concern for health authorities and now the
focus is on preventing their spread [2].
- Class D carbapenemases are represented by OXA-48, which is exclusive for Enterobacteriaceae.
They are well distributed among all enterobacterial species with high prevalence (Figure 2). OXA-
48 enzymes have a weak carbapenemase activity, therefore, they may go unnoticed for
susceptibility tests, complicating detection and control measures and making dissemination much
easier [2].
There is no universal method able to detect all types of carbapenemase producers with
high sensitivity and specificity. Detection of CPE is first based on an analysis of
susceptibility testing results, but automated systems may not reliably detect all types
of carbapenemase producers and here is when first discrepancies arise. CLSI and
EUCAST have set some breakpoints for susceptibility testing, but some studies
conclude that these breakpoints should be lowered and other characteristics should be
considered in order to detect any slight decrease in susceptibility to carbapenems to
obtain more accurate results [3,5].
If the susceptibility test results from an isolate are positive, carbapenemase production
have to be detected. A series of phenotypic and molecular tests for detection of
carbapenemase activity are discussed in Table 1:
Figure 3. Flowchart for detection and characterization of
carbapenemase producers among Enterobacteriaceae.
Molecular techniques (PCR, DNA microarray, sequencing)
only for precise identification of carbapenemase genes.
This step may be followed only in university hospitals or
large microbiology laboratories [1]
The emergence of CPE as a substantial
threat to health care should prompt
health authorities to formulate a
preparedness plan ready for
implementation, ensuring early
detection with standardized methods
and accurate treatment. In this area,
treatment with combination therapy
seems the best option, although new
resistances may still arise. A future
alternative might be the development of
new molecules targeting bacterial
metabolism. Furthermore, inhibition of
carbapenemases through the interaction
of molecules with the carbapenemase
active site has also been suggested.
However, the fast transmission of these
resistances and the genetic plasticity of
bacteria make this challenge even more
unlikely.
Conclusions
Figure 4. Outcomes of infections caused by CPE, according to treatment
regimen. Regimen A, combination therapy with ≥2 active drugs, one of which
was a carbapenem; regimen B, combination therapy with ≥2 active drugs, not
including a carbapenem; regimen C, monotherapy with an aminoglycoside;
regimen D, monotherapy with a carbapenem; regimen E, monotherapy with
tigecycline; regimen F, monotherapy with colistin; regimen G, inappropriate
therapy [4].
Figure 1. NDM producing Escherichia coli
http://www.bioquell.ie/technology/microbiology/new-delhi-metallo-beta-
lactamase-1-ndm-1/
Figure 2. Dortet et al. Characterized 172 carbapenemase producers
using DNA microarray + sequencing. 65% of CPE were K.pneumoniae,
15% were E.coli, 13% were Enterobacter spp. and 7% belonged to other
enterobacterial species. The identified carbapenemases were of the OXA-
48 (72%), KPC (15%), NDM (6%), VIM (6%), and IMI types (1%) [1].
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According to recent data from the Centers for Disease Control and Prevention in the United
States, the percentage of CPE increased almost ten times from 2001 to 2011, and it also has
been shown that patients with these infections experience fatality rates of 50 %. An important
question which still unanswered among clinicians is whether combination or monotherapy
antibiotic regimens are more effective. Tzouvelekis et al. [4] performed a study to evaluate
different antibiotic regimens (Figure 4). Results show that treatment failure was more common in
patients who were treated with monotherapy (colistin, tigecycline and aminoglycoside).
However, lower fatality rates are shown in patients treated with combination regimes. This may
be due to synergic effect of the drugs
and lesser probabilities to acquire
resistances.
Based on this study, it seems that
carbapenems retain some therapeutic
efficacy against CPE infections.
According to these results, combined
therapy with a carbapenem and another
active drug (colistin or aminoglycoside)
reduces fatality rates, and therefore,
could be the best treatment strategy.
Nevertheless, caution must be taken
because resistances, although less
probably, may still arise [5].
Carbapenemases are encoded mostly by bla
genes carried on mobile elements (e.g.
plasmids and/or integrons) that facilitates
their horizontal spread among different
Gram-negative species.
Three types of carbapenemases have been
identified:
-Class A carbapenemases (KPC, IMI, SME
and GES types) are often carried by
Klebsiella pneumoniae isolates, but they
have been found also in other
enterobacterial species like Klebsiella
oxytoca, Salmonella enterica, Proteus
mirabilis or Serratia marcescens (Figure 2).
KPC producers are the most clinically
common, they are able to hydrolyze all β-
lactams and most of the other antibiotic
families [2].
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